Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-676 (dazostinag) alone and with pembrolizumab in advanced or metastatic solid tumors
2023-505627-30-00Phase 2Completed
- Sponsor
- Takeda
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 12
01
Overview
Phase 2, open-label trial of dazostinag and pembrolizumab in Nonhematologic neoplasms, head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC) (7 arms), sponsored by Takeda. Primary endpoints: Frequency and severity of treatment-emergent adverse events, Dose-limiting toxicities and 3 more. Started Jun 2024; status: completed.
02
Drugs
dazostinagpembrolizumab
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-505627-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505627-30-00.